Loading...
XKRX
063160
Market cap80mUSD
Dec 05, Last price  
21,500.00KRW
1D
0.23%
1Q
-8.32%
Jan 2017
-4.14%
IPO
504.78%
Name

CKD Bio Corp

Chart & Performance

D1W1MN
XKRX:063160 chart
P/E
13.56
P/S
0.69
EPS
1,586.02
Div Yield, %
—
Shrs. gr., 5y
1.35%
Rev. gr., 5y
4.60%
Revenues
171.76b
+7.11%
66,409,841,00083,393,222,000106,553,579,000121,568,352,000110,527,721,450113,759,577,680100,370,797,420106,389,740,550106,690,657,800113,013,402,140118,187,072,160124,510,019,000137,184,188,550124,599,959,410142,238,418,400156,042,327,040160,352,778,354171,756,009,000
Net income
8.70b
P
-3,273,392,0008,737,629,00016,183,929,00014,375,712,00010,920,596,3707,101,290,0801,657,448,850-1,105,050,1406,653,133,0009,434,614,7508,016,298,6207,956,187,16012,264,879,9606,207,398,430-6,576,601,340-16,702,615,620-24,192,519,6408,700,827,000
CFO
14.03b
P
408,087,00010,689,037,00026,573,028,00023,887,459,00012,963,470,55022,900,061,37010,924,090,05011,222,959,39014,338,941,94015,500,000,86020,445,524,66015,535,533,73016,990,277,0004,824,020,040-5,882,180,150-3,204,562,880-7,223,883,84414,031,126,000
Dividend
Dec 29, 2021100 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

CKD Bio Corp. manufactures and distributes drug substances based on fermentation, synthesis, and biotechnology in South Korea. It offers drug substances in the areas of antibiotic, ß-lactamase inhibitors, immunosuppressants, anticancer drugs, obesity treatment drugs, dry eye, antivirus, antituberculosis, antihyperlipidemics, and probiotics. The company also provides contract research and development, and manufacturing services for active pharmaceutical ingredients and intermediates, and probiotics. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.
URL
https://www.ckdbio.com/
IPO date
Dec 11, 2001
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT